Insights

Strategic partnerships BrainsWay is actively pursuing strategic investments and minority stakes in mental health providers, signaling a preference for channel expansion and co-marketing opportunities with growth-oriented clinics to broaden access to Deep TMS.

Expansion potential With ongoing clinical trials and global offices in the US and Israel, there is clear opportunity to partner with regional distributors, hospital networks, and outpatient centers to scale adoption of Deep TMS across additional markets.

Clinical evidence Bringing three FDA-cleared indications backed by pivotal studies, plus real-world data on comorbid PTSD and MDD, positions the company as a leading partner for payors, hospitals, and clinics seeking proven, noninvasive neurostimulation solutions.

Funding signals Recent funding and investment activity, including strategic investments in mental health providers, indicates appetite for growth collaborations and co-funded programs to raise awareness and drive utilization of Deep TMS.

Market credibility Publicizing favorable industry coverage and momentum signals from investment and stock-positive narratives can be leveraged to build credibility with larger healthcare systems, distributors, and strategic buyers seeking innovative mental health tech.

BrainsWay Tech Stack

BrainsWay uses 8 technology products and services including Twitter Ads, Drupal, Outbrain, and more. Explore BrainsWay's tech stack below.

  • Twitter Ads
    Advertising
  • Drupal
    Content Management System
  • Outbrain
    Content Marketing
  • Salesforce
    Customer Relationship Management
  • StackAdapt
    Demand Side Platforms
  • Preact
    Javascript Libraries
  • Nginx
    Web Servers
  • Conditional Fields for Contact Form 7
    Widgets

Media & News

BrainsWay's Email Address Formats

BrainsWay uses at least 1 format(s):
BrainsWay Email FormatsExamplePercentage
First.Last@brainsway.comJohn.Doe@brainsway.com
63%
First@brainsway.comJohn@brainsway.com
20%
FirstLast@brainsway.comJohnDoe@brainsway.com
9%
Last@brainsway.comDoe@brainsway.com
8%

Frequently Asked Questions

What is BrainsWay's stock symbol?

Minus sign iconPlus sign icon
BrainsWay is a publicly traded company; the company's stock symbol is BWAY.

What is BrainsWay's official website and social media links?

Minus sign iconPlus sign icon
BrainsWay's official website is brainsway.com and has social profiles on LinkedInCrunchbase.

How much revenue does BrainsWay generate?

Minus sign iconPlus sign icon
As of July 2026, BrainsWay's annual revenue is estimated to be $25M - $50M.

What is BrainsWay's NAICS code?

Minus sign iconPlus sign icon
BrainsWay's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does BrainsWay have currently?

Minus sign iconPlus sign icon
As of July 2026, BrainsWay has approximately 145 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: H. L.Cfo: I. M.Chief Technology Officer: G. M.. Explore BrainsWay's employee directory with LeadIQ.

What industry does BrainsWay belong to?

Minus sign iconPlus sign icon
BrainsWay operates in the Medical Equipment Manufacturing industry.

What technology does BrainsWay use?

Minus sign iconPlus sign icon
BrainsWay's tech stack includes Twitter AdsDrupalOutbrainSalesforceStackAdaptPreactNginxConditional Fields for Contact Form 7.

What is BrainsWay's email format?

Minus sign iconPlus sign icon
BrainsWay's email format typically follows the pattern of First.Last@brainsway.com. Find more BrainsWay email formats with LeadIQ.

How much funding has BrainsWay raised to date?

Minus sign iconPlus sign icon
As of July 2026, BrainsWay has raised $20M in funding. The last funding round occurred on Oct 30, 2024 for $20M.

When was BrainsWay founded?

Minus sign iconPlus sign icon
BrainsWay was founded in 2003.
BrainsWay logo

BrainsWay

Medical Equipment ManufacturingMassachusetts, United States51-200 Employees

BrainsWay is a medical equipment manufacturer focused on noninvasive neurostimulation therapies for mental health disorders. Its Deep Transcranial Magnetic Stimulation platform has three FDA-cleared indications, supported by pivotal studies, for major depressive disorder (including anxious depression), obsessive-compulsive disorder, and smoking addiction. The company emphasizes building a robust clinical evidence base and expanding global awareness and access to Deep TMS.

Headquartered in Burlington, Massachusetts, with an office in Jerusalem, BrainsWay was founded in 2003 and operates as a mid-sized company. Its work centers on advancing clinical evidence and broadening access through ongoing trials across psychiatric, neurological, and addiction disorders. In June 2026, BrainsWay presented durability data from its accelerated Deep TMS program at the Clinical TMS Society Annual Meeting, reporting a remission rate exceeding 80% one year after treatment and a substantial reduction in severe functional impairment.

Section iconCompany Overview

Stock Symbol
BWAY
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2003
Employees
51-200

Section iconFunding & Financials

  • $20M

    BrainsWay has raised a total of $20M of funding over 5 rounds. Their latest funding round was raised on Oct 30, 2024 in the amount of $20M.

  • $25M - $50M

    BrainsWay's revenue is estimated to be in the range of $25M - $50M

Section iconFunding & Financials

  • $20M

    BrainsWay has raised a total of $20M of funding over 5 rounds. Their latest funding round was raised on Oct 30, 2024 in the amount of $20M.

  • $25M - $50M

    BrainsWay's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.